Relation of stavudine discontinuation to anthropometric changes among HIV-infected women.
OBJECTIVE
To characterize changes in regional anthropometry associated with stavudine exposure and discontinuation.


METHODS
Seven hundred thirty-four HIV-infected participants who reported using stavudine (574 of whom later discontinued stavudine) and 698 HIV-uninfected participants from the Women's Interagency HIV Study provided anthropometrics at 8706 semiannual visits between July 1999 and March 2005.


METHODS
Changes in weight, waist, chest, upper arm, hip, and midthigh circumferences were evaluated using linear regression with generalized estimating equations.


RESULTS
HIV-uninfected women demonstrated increases in regional anthropometry at every body site, whereas HIV-infected women demonstrated decreases in weight and circumferences of the waist, chest, hip, and thigh. A smaller annual decrease in hip circumference was seen after discontinuing stavudine for >2.25 years compared with the decrease observed while on stavudine (P = 0.01). Discontinuing stavudine for >2.25 years was associated with smaller (P < 0.05) decreases in hip (-0.06 cm/y) and thigh (-0.005 cm/y) circumference compared with the decreases observed between 1 and 2.25 years (hip: -0.46 cm/y, thigh: -0.24 cm/y) or < or =1 year (hip: -0.64 cm/y, thigh: -0.27 cm/y) after stavudine discontinuation.


CONCLUSIONS
Regardless of continuing or discontinuing stavudine, HIV-infected women demonstrate decreases in weight and body circumference measurements over time. The lower limb seems to be most affected by stavudine exposure, with stabilization observed more than 2 years after discontinuation.
Tien
Phyllis C
PC
Department of Medicine, University of California, San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA. ptien@ucsf.edu
Schneider
Michael F
MF
Cole
Stephen R
SR
Justman
Jessica E
JE
French
Audrey L
AL
Young
Mary
M
DeHovitz
Jack
J
Nathwani
Niyati
N
Brown
Todd T
TT
D000328:Adult; D000886:Anthropometry; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D039682:HIV-Associated Lipodystrophy Syndrome / Q000097:blood / Q000139:chemically induced / Q000473:pathology; D006615:Hip / Q000033:anatomy & histology; D006801:Humans; D018119:Stavudine / Q000008:administration & dosage* / Q000009:adverse effects
D019380:Anti-HIV Agents; D018119:Stavudine